🎉 M&A multiples are live!
Check it out!

Voronoi Valuation Multiples

Discover revenue and EBITDA valuation multiples for Voronoi and similar public comparables like Vivoryon Therapeutics, Julphar, and Benevolent AI.

Voronoi Overview

About Voronoi

Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders.


Founded

2015

HQ

South Korea
Employees

n/a

Website

voronoi.io

Financials

LTM Revenue $6.7M

LTM EBITDA -$17.7M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Voronoi Financials

Voronoi has a last 12-month revenue of $6.7M and a last 12-month EBITDA of -$17.7M.

In the most recent fiscal year, Voronoi achieved revenue of n/a and an EBITDA of -$20.5M.

Voronoi expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Voronoi valuation multiples based on analyst estimates

Voronoi P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit $6.7M n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$21.5M -$20.5M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$13.6M -$25.1M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt $9.7M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Voronoi Stock Performance

As of April 15, 2025, Voronoi's stock price is KRW 115600 (or $79).

Voronoi has current market cap of KRW 2.08T (or $1.4B), and EV of KRW 2.02T (or $1.4B).

See Voronoi trading valuation data

Voronoi Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $1.4B XXX XXX XXX XXX $-1.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Voronoi Valuation Multiples

As of April 15, 2025, Voronoi has market cap of $1.4B and EV of $1.4B.

Voronoi's trades at 206.7x LTM EV/Revenue multiple, and -77.9x LTM EBITDA.

Analysts estimate Voronoi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Voronoi and 10K+ public comps

Voronoi Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.4B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -67.2x XXX XXX XXX
P/E -63.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -66.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Voronoi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Voronoi Valuation Multiples

Voronoi's NTM/LTM revenue growth is 224%

Voronoi's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Voronoi's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Voronoi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Voronoi and other 10K+ public comps

Voronoi Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Voronoi Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Voronoi M&A and Investment Activity

Voronoi acquired  XXX companies to date.

Last acquisition by Voronoi was  XXXXXXXX, XXXXX XXXXX XXXXXX . Voronoi acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Voronoi

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Voronoi

When was Voronoi founded? Voronoi was founded in 2015.
Where is Voronoi headquartered? Voronoi is headquartered in South Korea.
Who is the CEO of Voronoi? Voronoi's CEO is Mr. Hyun-Tae Kim.
Is Voronoi publicy listed? Yes, Voronoi is a public company listed on KRX.
What is the stock symbol of Voronoi? Voronoi trades under 310210 ticker.
When did Voronoi go public? Voronoi went public in 2022.
Who are competitors of Voronoi? Similar companies to Voronoi include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Voronoi? Voronoi's current market cap is $1.4B
What is the current revenue of Voronoi? Voronoi's last 12-month revenue is $6.7M.
What is the current EBITDA of Voronoi? Voronoi's last 12-month EBITDA is -$17.7M.
What is the current EV/Revenue multiple of Voronoi? Current revenue multiple of Voronoi is 206.7x.
What is the current EV/EBITDA multiple of Voronoi? Current EBITDA multiple of Voronoi is -77.9x.
Is Voronoi profitable? Yes, Voronoi is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.